Can Anakinra and corticosteroid treatment be an effective option in pregnant women with severe Covid-19?


Creative Commons License

Karakaş Ö., Erden A., Ünlü S., Erol S. A., Goncu Ayhan Ş., Özdemir B., ...More

Women and Health, vol.61, no.9, pp.872-879, 2021 (SSCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 61 Issue: 9
  • Publication Date: 2021
  • Doi Number: 10.1080/03630242.2021.1981517
  • Journal Name: Women and Health
  • Journal Indexes: Social Sciences Citation Index (SSCI), Scopus, Academic Search Premier, IBZ Online, Periodicals Index Online, AgeLine, CAB Abstracts, CINAHL, Educational research abstracts (ERA), EMBASE, Gender Studies Database, MEDLINE, PAIS International, Psycinfo, Public Affairs Index, Social services abstracts, Sociological abstracts, Violence & Abuse Abstracts
  • Page Numbers: pp.872-879
  • Keywords: Anakinra, corticosteroid, Covid-19, cytokine storm, methylprednisolone, pregnant
  • Gazi University Affiliated: No

Abstract

© 2021 Taylor & Francis Group, LLC.Anakinra, which is an Interleukin-1 (IL-1) receptor antagonist with the advancing disease process, has started to be considered as an alternative treatment for Covid-19 patients with cytokine storms. We evaluated the effect of corticosteroids and IL-1 receptor blockage with anakinra on pregnant patients with Covid-19 at high risk for respiratory distress, ongoing fever, deterioration in their general condition and consequently maternal and fetal complications. Fourteen pregnant women who received anakinra (median dosage: 400 mg) and corticosteroid (methylprednisolone-median dosage: 80 mg) treatment were evaluated retrospectively. Patients were assessed according to the World Health Organization (WHO) scale. The mortality rate of the cohort was 7.1%, the median hospitalization period of the patients was 15 days and 2 patients had premature births. Covid-19 was found to have a similar spectrum of symptoms in pregnant and non-pregnant women, such as dyspnea, cough and fever. Our study was the first to analyze the combined treatment of corticosteroid and anakinra in pregnant patients with pneumonia from Covid-19 based on the WHO scoring system. Due to the obscurity in the treatment process in pregnant patients, studies are ongoing on managing Covid-19 infection in these patients. We presume that the early use of anakinra and corticosteroid treatments in patients severely infected with Covid-19 may have positive effects on disease progression and survival.